Novartis(US:NVS) Globenewswire·2026-02-24 12:15Core Insights - Novartis announced new real-world studies on Pluvicto™ for metastatic prostate cancer, utilizing data from the PRECISION platform, to be presented at the ASCO Genitourinary Cancers Symposium [1] Group 1: Efficacy of Pluvicto - Pluvicto demonstrated a median progression-free survival (PFS) of 13.5 months in taxane-naïve mCRPC patients who had received at least one ARPI, with longer PFS observed in those treated after one ARPI (15.8 months) compared to multiple ARPIs (12.7 months) [2][3] - The findings align with the PSMAfore trial, which showed that Pluvicto more than doubled median rPFS compared to a change in ARPI (11.6 months vs. 5.6 months) [3] Group 2: Subsequent Therapies - A study indicated that mCRPC patients achieved meaningful clinical responses with systemic therapies after discontinuing Pluvicto, with median PFS of 8.6 months for all subsequent therapies [5][6] - Patients receiving ARPI after Pluvicto had a median PFS of 10.7 months, while those receiving taxane had a median PFS of 7.2 months [6] Group 3: Treatment Patterns and Guidelines - Real-world evidence showed significant gaps in guideline adherence for metastatic hormone-sensitive prostate cancer (mHSPC), with 39.2% of men receiving ADT monotherapy instead of the recommended combination therapy [8] - The data highlights an opportunity for improved patient care through adherence to clinical guidelines [8] Group 4: PRECISION Data Platform - The PRECISION platform harmonizes data from over 56,500 patients with metastatic prostate cancer to generate real-world evidence studies that inform clinical decisions [9]